Meet The Board

Ron is a highly experienced and entrepreneurial Chair. Based in the USA, he is former President & CEO of Oncocyte, former member Board of Governors of ASCO’s CancerLinq program, and President, Genetic Sciences Division, Thermo Fisher Scientific. He has extensive corporate and investor contacts, having raised over $100m in growth capital.

Inventor with over two decades of experience in the field of clinical spectroscopy. Former Reader at University of Strathclyde. Top 6 KPMG Best British Tech Pioneers (2020), Fellowship of the Society for Applied Spectroscopy (2020), Top 40 under 40 Analytical Scientists (2018), RSC Harrison Meldola Prize (2017) and Emerging Leader in Molecular Spectroscopy (2016). Professor of Early Diagnostics, School of Medicine, University of Central Lancashire.

A Chartered Accountant and leader in business financing through private equity and VC investments.

Stacy Chick, is an experienced global commercial life sciences executive, advising Dxcover since 2021.  As Chief Commercial Officer for Inivata (acquired by NeoGenomics) and Kiyatec, Stacy successfully transitioned diagnostic innovations from research to commercial stage, developed markets, built commercial operations, and scaled revenues at optimal reimbursement rates.  She previously led area sales, operations, analytics and market access teams at Sanofi. Her strategic insights into global market access, reimbursement, and commercial scaling will guide Dxcover through its go-to-market strategy and CLIA rollout.

Chief Executive Officer of Altoida, is a seasoned health technology executive with over 25 years’ experience leading diagnostics, software, and AI-powered platforms. He has successfully driven multiple FDA-cleared and CE-marked products through development, approval, and commercial scale-up. At Altoida, Marc leads the development of digital biomarkers for neurological diseases using artificial intelligence and real-world data — experience directly aligned with Dxcover’s mission to deliver accessible, AI-driven cancer detection tools.

Strong track record as a diagnostics leader. Former Founder & CEO of DxS (sold to Qiagen for $130M), former R&D Manager Astra Zeneca Diagnostics, and current Vice Chairman at Yourgene Health.

Representing Norcliffe Capital Limited, Prof Onions has extensive experience in growing and commercializing businesses in the Life Sciences and Biotech sector.

A leader in the clinical spectroscopy field. Research Associate at University of Strathclyde and current MBA candidate. ‘Young Entrepreneur’ of the year winner, 2017 – Scottish Women’s Awards ‘Women in Innovation’ winner, 2017 – Global Game Changers Awards. Experienced researcher in biophotonics and infrared analysis.

Over two decades of experience in the field of data analysis and machine learning. Computational chemist, leading the design and development of the Dxcover diagnostic algorithms. Reader in Chemistry at the University of Strathclyde.

Andrew McNeill is managing partner at Eos Advisory, the St Andrews-based investment firm focused on science, engineering and technology innovation “that positively impacts our world”.

Professor of Neurosurgery at the University of Edinburgh and a globally recognised expert in brain cancer diagnostics. Professor Brennan has been instrumental in leading multiple clinical trials focused on the early detection and surgical management of brain tumours. His collaboration with Dxcover has contributed significantly to the development of real-world evidence supporting the platform’s ability to triage patients presenting with brain cancer symptoms in primary care.

Professor of Neurology and Neurosurgery at Duke University Medical Center, is a renowned expert in neuro-oncology and clinical trial design. She brings deep knowledge of brain cancer care pathways and is actively engaged in translational research to bring diagnostic innovations to the clinic.

Vice Chair of Clinical Affairs and Director of the Elkins Pancreas Center at Baylor College of Medicine, is a leading authority in pancreatic surgery and oncology. His insights into high-mortality, hard-to-detect cancers will inform Dxcover’s pathway to address urgent clinical needs in pancreatic cancer diagnostics.

Radiation Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), specialising in CNS malignancies. Dr. Pike brings a unique blend of clinical oncology expertise and real-world insights into US payer pathways, diagnostic adoption, and clinical utility. His contributions support Dxcover’s strategy to align its scientific development with healthcare system needs and reimbursement models in the United States.

Professor of Gynaecological Oncology at The University of Manchester and NIHR Research Professor, is an internationally respected clinician-scientist focused on early detection and prevention of endometrial and ovarian cancers. Her clinical trial experience and biomarker research expertise will support Dxcover’s development of  early detection strategies.